Study (author, year) | Number of patients | Age of subjects (years) | Study duration (weeks) | Drug /Dose | Diagnostic criteria | Respond criteria | Remission criteria | Outcome measures |
---|---|---|---|---|---|---|---|---|
Cutler AJ 2009 | 461 | 18–65 | 8 | Quetiapine XR/150 and 300 mg/day | DSM IV | ≥ 50% reduction in MADRS | MADRS ≤ 8 | MADRS, HAM-D, HAM-A, CGI-S, CGI-I, PSQI, SAS, BARS, CSFQ, 18-item TDSS scale |
Weisler R 2009 | 700 | 18–65 | 8 | Quetiapine XR/50, 150 and 300 mg/day | DSM IV | ≥ 50% reduction in MADRS | MADRS ≤ 8 | MADRS, HAM-D, HAM-A, CGI-S, CGI-I, PSQI, SAS, BARS, CSFQ, Q-LES-Q, 18-item TDSS scale |
Bortnick B 2011 | 299 | 18–65 | 10 | Quetiapine XR/150 to 300 mg/day | DSM IV | ≥ 50% reduction in MADRS | MADRS ≤ 8 | MADRS, HAM-D, HAM-A, CGI-S, CGI-I, PSQI, SAS, BARS, CSFQ, Q-LES-Q, 18-item TDSS scale |